Intellia is a genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. This technology offers the potential to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. Intellia's combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (14-Jun-2018)
Closing share price (14-Jun-2018)
General and administrative expense
Operating expense total
Depreciation and Amortization